You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCanagliflozin
Accession NumberDB08907
TypeSmall Molecule
GroupsApproved
DescriptionCanagliflozin belongs to a new class of anti-diabetic drugs that works by inhibiting the sodium-glucose transport protein (SGLT2). This transport protein is found in the kidney and is responsible for reabsorbing glucose that has been filtered. FDA approved on March 29, 2013.
Structure
Thumb
Synonyms
Canagliflozin anhydrous
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
InvokanaTablet100 mgOralJanssen Inc2014-06-03Not applicableCanada
InvokanaTablet300 mgOralJanssen Inc2014-05-28Not applicableCanada
InvokanaTablet, film coated100 mg/1OralJanssen Pharmaceuticals, Inc.2013-03-29Not applicableUs
InvokanaTablet, film coated300 mg/1OralJanssen Pharmaceuticals, Inc.2013-03-29Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
InvokametJanssen Pharmaceuticals, Inc.
Invokamet XRJanssen Pharmaceuticals, Inc.
Salts
Name/CASStructureProperties
Canagliflozin hydrate
928672-86-0
Thumb
  • InChI Key: VHOFTEAWFCUTOS-TUGBYPPCSA-N
  • Monoisotopic Mass: 906.291911168
  • Average Mass: 907.05
DBSALT001783
Categories
UNII6S49DGR869
CAS number842133-18-0
WeightAverage: 444.516
Monoisotopic: 444.140672805
Chemical FormulaC24H25FO5S
InChI KeyXTNGUQKDFGDXSJ-ZXGKGEBGSA-N
InChI
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES
[H][C@]1(O[[email protected]](CO)[C@@H](O)[[email protected]](O)[[email protected]]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1
Pharmacology
IndicationCanagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Use in type 1 diabetes mellitus patients or in treatment of diabetic ketoacidosis is not recommended.
Structured Indications
PharmacodynamicsCanagliflozin binds to SGLT2 more potently (250-times) than SGLT1 in vitro. The 50% inhibitory concentrations (IC50) are 2.2-4.4 nmol/L and 684 - 910 nmol/L for SGLT2 and SGLT1 respectively. Dose dependent decreases in renal threshold for glucose and increases in urinary glucose excretion were observed when single and multiple oral doses were administered to type 2 diabetes patients. Decreases in plasma glucose in a dose-dependent fashion were also noted as early as the first day of administration. When given to healthy and type 2 diabetic patients before a meal, a delay in intestinal glucose absorption and a reduction in postprandial glucose was observed. Canagliflozin does not prolong the QTc interval.
Mechanism of actionSodium-glucose co-transporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RTG), and thereby increases urinary glucose excretion.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium/glucose cotransporter 2Proteinyes
inhibitor
HumanP31639 details
Sodium/glucose cotransporter 1Proteinunknown
inhibitor
HumanP13866 details
Related Articles
AbsorptionThe pharmacokinetics of canagliflozin is similar in healthy subjects and patients with type 2 diabetes. Plasma Cmax and AUC of canagliflozin increased in a dose-proportional manner from 50 mg to 300 mg. Accumulation in plasma has been observed following multiple doses of 100 - 300 mg. Food does not affect the absorption of canagliflozin. Tmax = 1- 2 hours; Cmax = 1059 - 3148 ng/mL; Time to steady state, once daily dose, 100 - 300 mg = 4-5 days; Absolute oral bioavailability = 65%.
Volume of distribution

Steady state, single IV infusion, healthy subject = 119 L. This high value suggests that cangliflozin is extensively distributed to tissue.

Protein binding>99% protein bound, mainly to albumin. It also binds to alpha-acid glycoprotein. Protein binding is independent of canagliflozin plasma concentrations. Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment.
Metabolism

Canagliflozin is hepatically metabolized via O-glucuronidation into two inactive O-glucuronide metabolites. The enzymes that facilitate this process are UGT1A9 and UGT2B4. To a lesser extent (7%), canagliflozin also undergoes oxidative metabolism via CYP3A4. Canagliflozin weakly inhibited CYP2B6, CYP2C8, CYP2C9, and CYP3A4 based on in vitro studies with human hepatic microsomes.

Route of eliminationEnterohepatic circulation of canagliflozin was negligible. When a single oral dose is administered to a healthy subject, canagliflozin is eliminated via the following: Feces (41.5%, 7.0%, 3.2% as canagliflozin, a hydroxylated metabolite, and an O-glucuronide metabolite, respectively). Urine (33%; 30.5% as O-glucuronide metabolite, <1% as unchanged drug).
Half lifeThe apparent terminal half-life (t1/2) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.
Clearance

Mean systemic clearance, healthy subjects, IV administration = 192 mL/min.
Renal clearance of canagliflozin 100 mg and 300 mg doses ranged from 1.30 to 1.55 mL/min.

ToxicityMost common adverse reactions associated with canagliflozin (5% or greater incidence): female genital mycotic infections, urinary tract infection, and increased urination.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Canagliflozin.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Canagliflozin.Approved
AcetaminophenThe serum concentration of Canagliflozin can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideCanagliflozin may increase the hypoglycemic activities of Acetohexamide.Withdrawn
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Canagliflozin.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Canagliflozin.Approved
AlbendazoleThe serum concentration of Canagliflozin can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.Approved
AldosteroneThe serum concentration of Canagliflozin can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Canagliflozin can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Canagliflozin can be increased when it is combined with Alfentanil.Approved, Illicit
AliskirenCanagliflozin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Canagliflozin.Approved, Investigational
AmantadineThe serum concentration of Canagliflozin can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Canagliflozin.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Amifostine.Approved, Investigational
AmilorideCanagliflozin may increase the hyperkalemic activities of Amiloride.Approved
Aminohippuric acidThe serum concentration of Canagliflozin can be increased when it is combined with Aminohippuric acid.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Canagliflozin.Approved
AmiodaroneThe metabolism of Canagliflozin can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Canagliflozin can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Canagliflozin.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Canagliflozin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Canagliflozin can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Canagliflozin can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Canagliflozin.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Canagliflozin.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Canagliflozin.Approved
AprepitantThe serum concentration of Canagliflozin can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Canagliflozin.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Canagliflozin.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Asenapine.Approved
AstemizoleThe serum concentration of Canagliflozin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Canagliflozin can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Canagliflozin.Approved
AtomoxetineThe metabolism of Canagliflozin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Canagliflozin can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Canagliflozin.Approved, Investigational
AzelastineThe serum concentration of Canagliflozin can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilCanagliflozin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Canagliflozin can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Canagliflozin.Experimental
BarbitalBarbital may increase the hypotensive activities of Canagliflozin.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Canagliflozin.Approved
BenazeprilCanagliflozin may increase the hyperkalemic activities of Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Canagliflozin.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Canagliflozin.Withdrawn
BenzocaineThe serum concentration of Canagliflozin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Canagliflozin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Canagliflozin.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Canagliflozin.Approved
BexaroteneThe serum concentration of Canagliflozin can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Canagliflozin can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Canagliflozin.Approved
BoceprevirThe metabolism of Canagliflozin can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Canagliflozin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Canagliflozin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Canagliflozin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Canagliflozin.Approved
BrexpiprazoleThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Canagliflozin.Approved
BromocriptineThe serum concentration of Canagliflozin can be increased when it is combined with Bromocriptine.Approved, Investigational
BumetanideCanagliflozin may increase the hypotensive activities of Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Bupivacaine.Approved, Investigational
BuprenorphineThe serum concentration of Canagliflozin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Buserelin.Approved
BuspironeThe serum concentration of Canagliflozin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Canagliflozin can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Canagliflozin can be increased when it is combined with Caffeine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Canagliflozin.Experimental
CandesartanCanagliflozin may increase the hyperkalemic activities of Candesartan.Approved
CandoxatrilCanagliflozin may increase the hyperkalemic activities of Candoxatril.Experimental
CaptoprilCanagliflozin may increase the hyperkalemic activities of Captopril.Approved
CarbamazepineThe serum concentration of Canagliflozin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Canagliflozin.Approved
CaroxazoneCaroxazone may increase the hypoglycemic activities of Canagliflozin.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Canagliflozin.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Canagliflozin.Approved, Investigational
CaspofunginThe serum concentration of Canagliflozin can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Canagliflozin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Canagliflozin.Withdrawn
CertoparinCertoparin may increase the hyperkalemic activities of Canagliflozin.Approved
ChloroquineThe serum concentration of Canagliflozin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Canagliflozin.Approved, Vet Approved
ChlorpromazineThe serum concentration of Canagliflozin can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideCanagliflozin may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Canagliflozin can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Canagliflozin.Approved
CholesterolThe serum concentration of Canagliflozin can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Canagliflozin can be decreased when it is combined with Cholic Acid.Approved
CilazaprilCanagliflozin may increase the hyperkalemic activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Canagliflozin can be decreased when it is combined with Cimetidine.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Withdrawn
CiprofloxacinThe serum concentration of Canagliflozin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Canagliflozin.Approved
CitalopramThe serum concentration of Canagliflozin can be increased when it is combined with Citalopram.Approved
ClarithromycinThe metabolism of Canagliflozin can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Canagliflozin can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Canagliflozin.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Canagliflozin.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Canagliflozin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Canagliflozin.Approved, Investigational
ClomipramineThe serum concentration of Canagliflozin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Canagliflozin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Canagliflozin.Approved, Nutraceutical
ClotrimazoleThe metabolism of Canagliflozin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Clozapine.Approved
CobicistatThe metabolism of Canagliflozin can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Canagliflozin.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Canagliflozin.Approved
ColforsinThe serum concentration of Canagliflozin can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Canagliflozin can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Canagliflozin.Approved
CorticotropinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cortisone acetate.Approved
CrizotinibThe metabolism of Canagliflozin can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Canagliflozin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Canagliflozin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Canagliflozin.Approved
DabrafenibThe serum concentration of Canagliflozin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Canagliflozin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Canagliflozin can be increased when it is combined with Dactinomycin.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Canagliflozin.Approved
DanazolThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Danazol.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Canagliflozin.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Canagliflozin.Investigational
DarunavirThe metabolism of Canagliflozin can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Canagliflozin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Canagliflozin can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Canagliflozin.Approved
DeferasiroxThe serum concentration of Canagliflozin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Canagliflozin can be decreased when combined with Delavirdine.Approved
dersalazinedersalazine may increase the hypoglycemic activities of Canagliflozin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Desflurane.Approved
DesipramineThe serum concentration of Canagliflozin can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Canagliflozin can be increased when it is combined with Desloratadine.Approved, Investigational
DesogestrelThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Canagliflozin.Approved
DexamethasoneThe serum concentration of Canagliflozin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Canagliflozin.Approved, Vet Approved
DextromethorphanThe serum concentration of Canagliflozin can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Canagliflozin.Approved, Illicit, Vet Approved
DiazoxideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diazoxide.Approved
DiclofenacThe serum concentration of Canagliflozin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Canagliflozin.Approved
DienogestThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Canagliflozin.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Canagliflozin.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Canagliflozin.Approved
DigoxinThe serum concentration of Canagliflozin can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Canagliflozin can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Canagliflozin.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Canagliflozin.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Canagliflozin.Approved
DisopyramideCanagliflozin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Canagliflozin.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Canagliflozin.Approved, Investigational, Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Canagliflozin.Approved
DoxepinThe serum concentration of Canagliflozin can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Canagliflozin.Approved, Investigational
DoxorubicinThe serum concentration of Canagliflozin can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Canagliflozin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Canagliflozin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Canagliflozin can be decreased when combined with Dronedarone.Approved
DrospirenoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Drospirenone.Approved
DuloxetineCanagliflozin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Canagliflozin.Approved
EfavirenzThe serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Efonidipine.Approved
ElbasvirThe serum concentration of Canagliflozin can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Canagliflozin.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Empagliflozin.Approved
EnalaprilCanagliflozin may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
EnalaprilatCanagliflozin may increase the hyperkalemic activities of Enalaprilat.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Canagliflozin.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Canagliflozin.Approved
EnzalutamideThe serum concentration of Canagliflozin can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Canagliflozin.Approved, Investigational
EpinephrineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EplerenoneCanagliflozin may increase the hyperkalemic activities of Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Epoprostenol.Approved
EprosartanCanagliflozin may increase the hyperkalemic activities of Eprosartan.Approved
ErgonovineThe serum concentration of Canagliflozin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Canagliflozin can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Canagliflozin.Approved, Investigational
ErythromycinThe metabolism of Canagliflozin can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Canagliflozin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Canagliflozin.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Canagliflozin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Canagliflozin can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Canagliflozin can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Canagliflozin can be decreased when it is combined with Estrone.Approved
Estrone sulfateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidCanagliflozin may increase the hypotensive activities of Etacrynic acid.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Canagliflozin.Approved
Ethynodiol diacetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethynodiol diacetate.Approved
EtonogestrelThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Canagliflozin.Approved
EtoposideThe serum concentration of Canagliflozin can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Canagliflozin can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Canagliflozin.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Canagliflozin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Canagliflozin.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Fenoldopam.Approved
FentanylThe serum concentration of Canagliflozin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Canagliflozin.Approved
FexofenadineThe serum concentration of Canagliflozin can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Canagliflozin can be increased when it is combined with Fidaxomicin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Fimasartan.Approved
FleroxacinFleroxacin may increase the hypoglycemic activities of Canagliflozin.Approved
FluconazoleThe metabolism of Canagliflozin can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fludrocortisone.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Canagliflozin.Withdrawn
FluoxetineThe serum concentration of Canagliflozin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Canagliflozin.Approved, Illicit
FlupentixolThe serum concentration of Canagliflozin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Canagliflozin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Canagliflozin can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Canagliflozin.Approved
FluvoxamineThe metabolism of Canagliflozin can be decreased when combined with Fluvoxamine.Approved, Investigational
ForasartanCanagliflozin may increase the hyperkalemic activities of Forasartan.Experimental
FosamprenavirThe metabolism of Canagliflozin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Canagliflozin can be increased when it is combined with Fosaprepitant.Approved
FosinoprilCanagliflozin may increase the hyperkalemic activities of Fosinopril.Approved
FosphenytoinThe serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Canagliflozin.Approved, Vet Approved
FurosemideCanagliflozin may increase the hypotensive activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Canagliflozin can be increased when it is combined with Fusidic Acid.Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Canagliflozin.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
GefitinibThe serum concentration of Canagliflozin can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Canagliflozin.Approved
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
GenisteinThe serum concentration of Canagliflozin can be increased when it is combined with Genistein.Investigational
GlibornurideCanagliflozin may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideCanagliflozin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideCanagliflozin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideCanagliflozin may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneCanagliflozin may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideCanagliflozin may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideCanagliflozin may increase the hypoglycemic activities of Glyburide.Approved
GlycerolThe serum concentration of Canagliflozin can be increased when it is combined with Glycerol.Experimental
GoserelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.Approved
Gramicidin DThe serum concentration of Canagliflozin can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Canagliflozin.Approved
GrepafloxacinThe serum concentration of Canagliflozin can be increased when it is combined with Grepafloxacin.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Canagliflozin.Approved, Investigational
HaloperidolThe serum concentration of Canagliflozin can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Canagliflozin.Approved, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Canagliflozin.Approved
HistrelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Canagliflozin.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Canagliflozin.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Canagliflozin.Approved, Vet Approved
HydrocortisoneThe serum concentration of Canagliflozin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Hydroflumethiazide.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Canagliflozin.Approved
IdelalisibThe serum concentration of Canagliflozin can be increased when it is combined with Idelalisib.Approved
IloperidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Iloprost.Approved, Investigational
ImatinibThe metabolism of Canagliflozin can be decreased when combined with Imatinib.Approved
ImidaprilCanagliflozin may increase the hyperkalemic activities of Imidapril.Investigational
ImipramineThe serum concentration of Canagliflozin can be increased when it is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Canagliflozin.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Canagliflozin.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Canagliflozin.Approved
IndinavirThe metabolism of Canagliflozin can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Canagliflozin can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Indoramin.Withdrawn
Insulin AspartCanagliflozin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirCanagliflozin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineCanagliflozin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineCanagliflozin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanCanagliflozin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproCanagliflozin may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin PorkCanagliflozin may increase the hypoglycemic activities of Insulin Pork.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Canagliflozin.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Canagliflozin.Withdrawn
IrbesartanCanagliflozin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Canagliflozin.Approved, Investigational
IsavuconazoniumThe metabolism of Canagliflozin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Canagliflozin.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Canagliflozin.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Canagliflozin.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Canagliflozin.Approved
ItraconazoleThe metabolism of Canagliflozin can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Canagliflozin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Canagliflozin can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Canagliflozin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Canagliflozin.Approved
KetoconazoleThe metabolism of Canagliflozin can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Canagliflozin.Approved
LacidipineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Canagliflozin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Canagliflozin.Approved, Investigational
LanreotideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lanreotide.Approved
LansoprazoleThe serum concentration of Canagliflozin can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Canagliflozin can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Canagliflozin.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Canagliflozin.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Canagliflozin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Lercanidipine.Approved, Investigational
LeuprolideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Canagliflozin.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Canagliflozin.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Levobupivacaine.Approved
LevodopaCanagliflozin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Canagliflozin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Canagliflozin.Approved
LevonorgestrelThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Canagliflozin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Canagliflozin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Canagliflozin.Approved
LiothyronineThe serum concentration of Canagliflozin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Canagliflozin can be decreased when it is combined with Liotrix.Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Canagliflozin.Approved, Nutraceutical
LisinoprilCanagliflozin may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Lofexidine.Approved, Investigational
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
LomitapideThe serum concentration of Canagliflozin can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Canagliflozin can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Canagliflozin can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Canagliflozin can be increased when it is combined with Loratadine.Approved
LosartanCanagliflozin may increase the hyperkalemic activities of Losartan.Approved
LovastatinThe metabolism of Canagliflozin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Canagliflozin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Canagliflozin can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Canagliflozin.Approved, Investigational
MaprotilineThe serum concentration of Canagliflozin can be increased when it is combined with Maprotiline.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Canagliflozin.Withdrawn
MebendazoleThe serum concentration of Canagliflozin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Canagliflozin.Approved
MecaserminCanagliflozin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
MefloquineThe serum concentration of Canagliflozin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Canagliflozin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Canagliflozin can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the hypoglycemic activities of Canagliflozin.Approved
MestranolThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Mestranol.Approved
MethadoneThe serum concentration of Canagliflozin can be increased when it is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Canagliflozin.Approved
MethohexitalMethohexital may increase the hypotensive activities of Canagliflozin.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Canagliflozin.Approved
MethotrimeprazineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Canagliflozin.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Canagliflozin.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Canagliflozin.Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Canagliflozin.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Canagliflozin.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Canagliflozin.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Canagliflozin.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Canagliflozin.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Canagliflozin.Approved, Investigational
MibefradilThe serum concentration of Canagliflozin can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Canagliflozin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Canagliflozin can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Canagliflozin can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the hypoglycemic activities of Canagliflozin.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Canagliflozin.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Canagliflozin.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Canagliflozin.Approved
MitomycinThe serum concentration of Canagliflozin can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Canagliflozin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Canagliflozin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideMoclobemide may increase the hypoglycemic activities of Canagliflozin.Approved
ModafinilThe serum concentration of Canagliflozin can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilCanagliflozin may increase the hyperkalemic activities of Moexipril.Approved
MorphineThe serum concentration of Canagliflozin can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Canagliflozin.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Canagliflozin.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Canagliflozin.Approved
NafcillinThe serum concentration of Canagliflozin can be decreased when it is combined with Nafcillin.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Canagliflozin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Canagliflozin.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Canagliflozin.Approved, Vet Approved
NaltrexoneThe serum concentration of Canagliflozin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Canagliflozin can be increased when it is combined with Naringenin.Experimental
NateglinideCanagliflozin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 4016NCX 4016 may increase the hypoglycemic activities of Canagliflozin.Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Canagliflozin.Approved, Investigational
NefazodoneThe metabolism of Canagliflozin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Canagliflozin can be decreased when combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Canagliflozin.Investigational
NeostigmineThe serum concentration of Canagliflozin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Canagliflozin.Approved, Investigational
NetupitantThe serum concentration of Canagliflozin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Canagliflozin can be increased when combined with Nevirapine.Approved
NiacinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Canagliflozin.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Canagliflozin.Approved
NicorandilNicorandil may increase the hypotensive activities of Canagliflozin.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Canagliflozin.Approved
NilotinibThe metabolism of Canagliflozin can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Canagliflozin.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Canagliflozin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Canagliflozin.Approved
NitrazepamThe serum concentration of Canagliflozin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Canagliflozin can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Canagliflozin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Canagliflozin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Canagliflozin.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Canagliflozin.Approved
NorethisteroneThe serum concentration of Canagliflozin can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
NorgestimateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norgestimate.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Canagliflozin.Withdrawn
OctreotideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.Approved, Investigational
OfloxacinOfloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Canagliflozin.Approved, Investigational
OlaparibThe metabolism of Canagliflozin can be decreased when combined with Olaparib.Approved
OlmesartanCanagliflozin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlsalazineOlsalazine may increase the hypoglycemic activities of Canagliflozin.Approved
OmapatrilatCanagliflozin may increase the hyperkalemic activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Canagliflozin.Approved
OmeprazoleThe serum concentration of Canagliflozin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Canagliflozin can be increased when it is combined with Osimertinib.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Oxprenolol.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Canagliflozin.Approved, Illicit
P-NitrophenolThe serum concentration of Canagliflozin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Canagliflozin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Canagliflozin can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Paliperidone.Approved
Palmitic AcidThe serum concentration of Canagliflozin can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Canagliflozin.Approved, Investigational
PantoprazoleThe serum concentration of Canagliflozin can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.Approved
PargylinePargyline may increase the hypoglycemic activities of Canagliflozin.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Canagliflozin.Approved
ParoxetineThe serum concentration of Canagliflozin can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Canagliflozin.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Canagliflozin.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Canagliflozin.Approved, Investigational
PentamidineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pentamidine.Approved
PentobarbitalThe metabolism of Canagliflozin can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilCanagliflozin may increase the hyperkalemic activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Canagliflozin.Approved
PheniprazinePheniprazine may increase the hypoglycemic activities of Canagliflozin.Withdrawn
PhenobarbitalThe serum concentration of Canagliflozin can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Canagliflozin.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Canagliflozin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Canagliflozin can be increased when it is combined with Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Canagliflozin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Pipamperone.Approved
PiperazineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pipotiazine.Approved
PiretanideCanagliflozin may increase the hypotensive activities of Piretanide.Experimental
PirlindolePirlindole may increase the hypoglycemic activities of Canagliflozin.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Canagliflozin.Approved
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Canagliflozin.Withdrawn
Platelet Activating FactorThe serum concentration of Canagliflozin can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Canagliflozin.Approved
PonatinibThe serum concentration of Canagliflozin can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Canagliflozin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Canagliflozin can be increased when it is combined with Pravastatin.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Canagliflozin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Canagliflozin.Approved, Vet Approved
PrednisoneThe serum concentration of Canagliflozin can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Canagliflozin can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Canagliflozin can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Canagliflozin can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Canagliflozin can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Canagliflozin can be increased when it is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Canagliflozin.Approved, Investigational
ProtriptylineThe serum concentration of Canagliflozin can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Canagliflozin.Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Canagliflozin.Investigational
QuercetinThe serum concentration of Canagliflozin can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Canagliflozin.Approved
QuinacrineThe serum concentration of Canagliflozin can be increased when it is combined with Quinacrine.Approved
QuinaprilCanagliflozin may increase the hyperkalemic activities of Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quinethazone.Approved
QuinidineThe serum concentration of Canagliflozin can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Canagliflozin can be increased when it is combined with Quinine.Approved
RamiprilCanagliflozin may increase the hyperkalemic activities of Ramipril.Approved
RanitidineThe serum concentration of Canagliflozin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Canagliflozin.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Canagliflozin.Approved
ReboxetineThe serum concentration of Canagliflozin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Canagliflozin can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Remifentanil.Approved
RepaglinideCanagliflozin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineCanagliflozin may increase the hyperkalemic activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Canagliflozin.Approved
ReviparinReviparin may increase the hyperkalemic activities of Canagliflozin.Approved
RifabutinThe metabolism of Canagliflozin can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Canagliflozin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Canagliflozin can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Canagliflozin.Approved, Investigational
RilpivirineThe serum concentration of Canagliflozin can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Riociguat.Approved
RisperidoneCanagliflozin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Canagliflozin can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Canagliflozin.Approved
RolapitantThe serum concentration of Canagliflozin can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Canagliflozin.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Ropivacaine.Approved
RosoxacinRosoxacin may increase the hypoglycemic activities of Canagliflozin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Rotigotine.Approved
SacubitrilCanagliflozin may increase the hyperkalemic activities of Sacubitril.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Canagliflozin.Withdrawn
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Canagliflozin.Approved, Vet Approved
SaprisartanCanagliflozin may increase the hyperkalemic activities of Saprisartan.Experimental
SaquinavirThe metabolism of Canagliflozin can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinCanagliflozin may increase the hyperkalemic activities of Saralasin.Investigational
ScopolamineThe serum concentration of Canagliflozin can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Canagliflozin.Approved, Vet Approved
SelegilineSelegiline may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Canagliflozin.Approved
SertralineThe serum concentration of Canagliflozin can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Canagliflozin can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Canagliflozin.Approved
SiltuximabThe serum concentration of Canagliflozin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Canagliflozin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Canagliflozin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Canagliflozin can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Canagliflozin.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Canagliflozin.Approved
SorafenibThe serum concentration of Canagliflozin can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Canagliflozin.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Canagliflozin.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Canagliflozin.Experimental
SpiraprilCanagliflozin may increase the hyperkalemic activities of Spirapril.Approved
SpironolactoneCanagliflozin may increase the hyperkalemic activities of Spironolactone.Approved
St. John's WortThe serum concentration of Canagliflozin can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StanozololStanozolol may increase the hypoglycemic activities of Canagliflozin.Approved, Vet Approved
StaurosporineThe serum concentration of Canagliflozin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Canagliflozin can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Canagliflozin can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Sufentanil.Approved, Investigational
SulfadiazineCanagliflozin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleCanagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Canagliflozin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Canagliflozin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Canagliflozin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Canagliflozin can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Canagliflozin can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Canagliflozin can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Canagliflozin can be decreased when it is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Tamsulosin.Approved, Investigational
TasosartanCanagliflozin may increase the hyperkalemic activities of Tasosartan.Approved
Taurocholic AcidThe serum concentration of Canagliflozin can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Canagliflozin.Approved
TelaprevirThe metabolism of Canagliflozin can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Canagliflozin can be decreased when combined with Telithromycin.Approved
TelmisartanCanagliflozin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Canagliflozin.Withdrawn
TemocaprilCanagliflozin may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Canagliflozin can be increased when it is combined with Temsirolimus.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Canagliflozin.Approved
TerfenadineThe serum concentration of Canagliflozin can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Canagliflozin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Canagliflozin can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Canagliflozin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Canagliflozin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Thioridazine.Approved
TicagrelorThe serum concentration of Canagliflozin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Canagliflozin can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Canagliflozin.Approved
TinzaparinTinzaparin may increase the hyperkalemic activities of Canagliflozin.Approved
TipranavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Canagliflozin.Approved
TocilizumabThe serum concentration of Canagliflozin can be decreased when it is combined with Tocilizumab.Approved
TolazamideCanagliflozin may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Tolazoline.Approved, Vet Approved
TolbutamideCanagliflozin may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Tolcapone.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypoglycemic activities of Canagliflozin.Approved
TolvaptanThe serum concentration of Canagliflozin can be increased when it is combined with Tolvaptan.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Canagliflozin.Approved, Investigational
TorasemideCanagliflozin may increase the hypotensive activities of Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Canagliflozin.Approved, Investigational
TrandolaprilCanagliflozin may increase the hyperkalemic activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Canagliflozin.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Canagliflozin.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Canagliflozin.Approved
TrazodoneThe serum concentration of Canagliflozin can be decreased when it is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TriamtereneCanagliflozin may increase the hyperkalemic activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Canagliflozin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Canagliflozin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Canagliflozin can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Canagliflozin can be increased when it is combined with Trimipramine.Approved
TriptorelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TroleandomycinThe serum concentration of Canagliflozin can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Withdrawn
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Canagliflozin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Canagliflozin.Approved
ValsartanCanagliflozin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Canagliflozin.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Canagliflozin.Approved
VenlafaxineThe metabolism of Canagliflozin can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Canagliflozin.Approved
VinblastineThe serum concentration of Canagliflozin can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Canagliflozin.Approved, Investigational
VincristineThe serum concentration of Canagliflozin can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Canagliflozin can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Canagliflozin.Approved
VoriconazoleThe metabolism of Canagliflozin can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Vorinostat.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Canagliflozin.Approved
ZimelidineThe serum concentration of Canagliflozin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Canagliflozin can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413 ]
External Links
ATC CodesA10BD16A10BX11
AHFS Codes
  • 68:20.18
PDB EntriesNot Available
FDA labelDownload (683 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9541
Blood Brain Barrier+0.7708
Caco-2 permeable-0.6554
P-glycoprotein substrateSubstrate0.6058
P-glycoprotein inhibitor INon-inhibitor0.8414
P-glycoprotein inhibitor IINon-inhibitor0.9447
Renal organic cation transporterNon-inhibitor0.8544
CYP450 2C9 substrateNon-substrate0.6853
CYP450 2D6 substrateNon-substrate0.8293
CYP450 3A4 substrateNon-substrate0.5929
CYP450 1A2 substrateNon-inhibitor0.6579
CYP450 2C9 inhibitorNon-inhibitor0.6178
CYP450 2D6 inhibitorNon-inhibitor0.8683
CYP450 2C19 inhibitorNon-inhibitor0.5958
CYP450 3A4 inhibitorNon-inhibitor0.7086
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7691
Ames testNon AMES toxic0.584
CarcinogenicityNon-carcinogens0.9103
BiodegradationNot ready biodegradable0.9936
Rat acute toxicity2.5975 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9912
hERG inhibition (predictor II)Non-inhibitor0.7246
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral
Tablet, film coated, extended releaseOral
TabletOral100 mg
TabletOral300 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral300 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7943582 No2009-02-262029-02-26Us
US7943788 No2007-07-142027-07-14Us
US8222219 No2004-07-302024-07-30Us
US8513202 No2007-12-032027-12-03Us
US8785403 No2004-07-302024-07-30Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0045 mg/mLALOGPS
logP3.09ALOGPS
logP3.52ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)12.57ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area90.15 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity116.14 m3·mol-1ChemAxon
Polarizability46.5 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassGlycosyl compounds
Direct ParentPhenolic glycosides
Alternative Parents
Substituents
  • Phenolic glycoside
  • C-glycosyl compound
  • 2,5-disubstituted thiophene
  • Toluene
  • Halobenzene
  • Fluorobenzene
  • Benzenoid
  • Oxane
  • Monosaccharide
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Thiophene
  • Secondary alcohol
  • Polyol
  • 1,2-diol
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Primary alcohol
  • Organofluoride
  • Organohalogen compound
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Low-affinity glucose:sodium symporter activity
Specific Function:
Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules.
Gene Name:
SLC5A2
Uniprot ID:
P31639
Molecular Weight:
72895.995 Da
References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Glucose:sodium symporter activity
Specific Function:
Actively transports glucose into cells by Na(+) cotransport with a Na(+) to glucose coupling ratio of 2:1. Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules.
Gene Name:
SLC5A1
Uniprot ID:
P13866
Molecular Weight:
73497.275 Da
References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as estriol, 4-hydroxyestrone and 2-hydroxyestriol) and xenobiotics (such as 4-methylumbelliferone, 1-naphthol, 4-nitrophenol, 2-aminophenol, 4-hydroxybiphenyl and menthol). It is capable of 6 alpha-hydr...
Gene Name:
UGT2B4
Uniprot ID:
P06133
Molecular Weight:
60512.035 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
Comments
comments powered by Disqus
Drug created on June 17, 2013 00:21 / Updated on December 04, 2016 02:45